Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2014-04-16 Share Issue/Capital Cha…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document announces that THERADIAG is setting up a 'PACEO®' financing line with Société Générale, which involves the potential issuance of up to 445,000 new shares over 24 months, subject to shareholder approval (delegated by the AGM on April 8, 2014). This action directly relates to fundraising, capital structure changes, and financing activities. Based on the definitions, this clearly falls under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). The document is a formal announcement detailing the terms of a financing agreement.
2014-04-16 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Environmental & Social Information Classification · 99% confidence The document is a press release dated April 8, 2014, announcing a new research partnership agreement between Theradiag and CNRS regarding microRNA development for Rheumatoid Arthritis (RA) diagnostics and theranostics. It details the scope of the agreement, quotes management, and provides company background. This type of announcement, detailing strategic business developments, partnerships, or significant operational news that is not a mandatory periodic financial filing (like 10-K or IR) or a specific event report (like AGM or Earnings), typically falls under general Regulatory Filings (RNS) or sometimes Investor Presentation (IP) if it were a slide deck. Given the content is a news announcement about a strategic agreement, and it doesn't fit the specific definitions for ER, CAP, LTR, or MANG, the most appropriate general category for non-standard corporate news announcements is RNS (Regulatory Filings/Miscellaneous Announcements). It is definitely not a full financial report (10-K, IR) or a report publication announcement (RPA) as it is the primary content itself, not an announcement *about* another report.
2014-04-08 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated April 8, 2014, announcing that THERADIAG has signed a new partnership agreement for microRNA research related to rheumatoid arthritis. It discusses strategic positioning, future product offerings, and management commentary. This type of announcement, detailing business development, partnerships, and strategic updates, does not fit the specific regulatory filings (10-K, IR, ER, DEF 14A, etc.). It is a general corporate announcement. Since it is not a report itself, nor a specific filing like Director's Dealing or Capital Change, the most appropriate general category for significant corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for press releases detailing operational news.
2014-04-08 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations, and provides a table detailing the total number of shares and voting rights as of a specific date (March 31, 2014). This type of mandatory disclosure regarding the capital structure and voting rights directly relates to changes in the share count or ownership structure. Among the provided definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate fit for a formal announcement detailing the total number of shares and voting rights, as this forms the basis for capital structure changes or shareholder voting calculations. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS).
2014-04-01 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 31, 2014, announcing that the company THERADIAG is eligible for the French PEA-PME tax incentive scheme. It details the criteria for eligibility (employee count, revenue/balance sheet limits) and the benefits of the scheme. This type of announcement, which relates to corporate structure, financing eligibility, or regulatory status changes that impact investment vehicles, fits best under 'Capital/Financing Update' (CAP) as it directly concerns the company's capital structure eligibility for specific investor accounts. It is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. Given the focus on a specific tax/investment vehicle eligibility, CAP is the most appropriate classification.
2014-03-31 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated March 27, 2014, announcing the unveiling of a new automated diagnostic solution (Theralis®) at a specific congress. It details product features, quotes the CEO, and provides company background and contact information. This type of announcement, focusing on a new product launch or significant operational update that is not a formal financial report (like 10-K, IR, or ER), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Product Launch Announcement' and it is not a formal financial filing, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous regulatory/news announcements that don't fit the specific financial report codes. The document length (3776 chars) is short, but it is a complete announcement, not just a notice that a report is attached, so RPA is less suitable than RNS for this type of news.
2014-03-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.